SCHEMBL12437405

SCHEMBL12437405

CCN(CC)CCNC(=O)c1ccccc1OC1CCN(CC(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
OPRK1 P41145 1/20 0.43
MCHR1 Q99705 3/20 0.41
CYP3A4 P08684 2/20 0.41
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
CHRM1 P11229 1/20 0.41
DRD1 P21728 1/20 0.41
SLC6A2 P23975 1/20 0.41
ADRA1A P35348 1/20 0.41
OPRM1 P35372 1/20 0.41
DRD3 P35462 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437408 0.90 MEN1 (0.51) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL12437458 0.89 MEN1 (0.52) MEN1KMT2ALMNAALDH1A1OPRK1
SCHEMBL12437457 0.87 MEN1 (0.54) MEN1KMT2ALMNAALDH1A1OPRK1
SCHEMBL12437466 0.85 POLB (0.50) MEN1KMT2ALMNAALDH1A1
SCHEMBL12437515 0.85 ALDH1A1 (0.54) MEN1KMT2ALMNAALDH1A1MCHR1
SCHEMBL12437416 0.84 MEN1 (0.50) MEN1KMT2ALMNAALDH1A1OPRK1
SCHEMBL12437383 0.83 MEN1 (0.49) MEN1KMT2ALMNAALDH1A1
SCHEMBL12437413 0.83 HRH3 (0.48) MEN1KMT2ALMNAALDH1A1
SCHEMBL12437381 0.83 HRH3 (0.48) MEN1KMT2ALMNAALDH1A1
SCHEMBL12437386 0.83 MEN1 (0.64) MEN1KMT2AOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof HPGDS, HPGD, DPYD MEN1 3974/4885KMT2A 2446/4885LMNA 2809/4885
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof HPGDS, HPGD, DPYD MEN1 3974/4885KMT2A 2446/4885LMNA 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.